Prelude Therapeutics Incorporated (PRLD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

As of Wednesday, February 25, Prelude Therapeutics Incorporated’s PRLD share price has surged by 9.62%, which has investors ...

Prelude Therapeutics Incorporated (PRLD) has been on a downward spiral lately with significant selling pressure. After declining 39.1% over the past four weeks, the stock looks well positioned for a ...

The average one-year price target for Prelude Therapeutics (NasdaqGS:PRLD) has been revised to $4.42 / share. This is an increase of 23.81% from the prior estimate of $3.57 dated September 27, 2025.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

What is the current share price of Prelude Therapeutics (PRLD)? Prelude Therapeutics's (PRLD) current share price is $4.00. This constitutes a price movement of 7.24% when compared to the share price ...

Every investor in Prelude Therapeutics Incorporated (NASDAQ:PRLD) should be aware of the most powerful shareholder groups. We can see that hedge funds own the lion's share in the company with 33% ...

As of 1:33:06 pm GMT-4. Market open. PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with ...